• 877-IWILFIN (494-5346)
  • IWILFIN Cares
  • Full Prescribing Information
  • For Caregivers
Patient Referral Form
IWILFIN HCP
Your browser does not support the audio element. Your browser does not support the audio element.
  • High-Risk Neuroblastoma Relapse
  • About IWILFIN
  • Clinical Data
    • Trial Design
    • Efficacy
    • Safety
  • Dosing & Administration
  • Prescribing & Resources
    • Prescribing
    • Resources
  • High-Risk Neuroblastoma Relapse
  • About IWILFIN
  • Clinical Data
  • Dosing & Administration
  • Presribing & Resources
Home / Safety
Important Safety Information

INDICATION

IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IWILFIN can cause myelosuppression and hepatotoxicity. CBC and liver function tests should be performed before starting treatment and as clinically indicated for the duration of treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity.

IWILFIN can cause hearing loss. Monitor hearing before and during treatment with IWILFIN. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity.

IWILFIN can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥5%) adverse reactions are hearing loss, otitis media, pyrexia, pneumonia, and diarrhea.
The most common (≥2%) Grade 3 or 4 laboratory abnormalities are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin.

INDICATION

IWILFIN is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

IWILFIN can cause myelosuppression and hepatotoxicity. CBC and liver function tests should be performed before starting treatment and as clinically indicated for the duration of treatment. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity.

IWILFIN can cause hearing loss. Monitor hearing before and during treatment with IWILFIN. Withhold, reduce the dose, or permanently discontinue IWILFIN based on severity.

IWILFIN can cause fetal harm. Advise females of reproductive potential of the possible risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥5%) adverse reactions are hearing loss, otitis media, pyrexia, pneumonia, and diarrhea.
The most common (≥2%) Grade 3 or 4 laboratory abnormalities are increased ALT, increased AST, decreased neutrophil count, and decreased hemoglobin.

©2024. USWM, LLC. All rights reserved.

US WorldMeds is a registered trademark of USWM, LLC.

IWILFIN is a registered trademark of USWM, LLC.

02/2024 US-USWM-00089

4441 Springdale Rd, Louisville, KY 40241 1-866-750-8796
  • Contact Us
  • Privacy Policy
  • Terms of Service